Facilitating Access to Approved Medication

Lorlatinib Tablets 25 mg
Lorlatinib Tablets, Lorviqua is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the disease is advanced and ALK-positive, which means that the cancer cells have certain changes affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase).

Get Access To Lorlatinib Tablets 25 mg

On March 3, 2021, the Food and Drug Administration granted regular approval to lorlatinib (Lorbrena, Pfizer Inc.) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive,  detected by an FDA-approved test.

Lorlatinib Tablets Available Price In India UK Saudi Arabia

Lorlatinib Tablets 

  • Innovator Brand Name – Ziagen
  • Generic Brand Available – Abamune
  • API – Lorlatinib
  • Packaging – 90 Tablets
  • Strength – 25 mg, 100 mg

What is Lorlatinib used for?

Lorlatinib is used to treat a certain type of lung cancer. It works by slowing or stopping the growth of cancer cells.



All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

Get Access To Lorlatinib Tablets 25 mg

Lucknow Speciality Pharma, Lucknow, India

Lucnow Speciality Pharma is registered in Lucknow, India. Registration Number : AAKFL2122J1ZB Under GST Act
Branch Offices in India : Lucknow | Agra | Jaipur | Varanasi | New Delhi

2nd Floor, 203-A, Felix Square, Golf City, Gomti Nagar, Lucknow, Uttar Pradesh 226030

Mobile :+91 97600 14849 / 9555306364
WhatsApp :+91 97600 14849 / 9555306364

Facts of Medicines

Lorlatinib Tablets 25 mg


The recommended dosage of Lorlatinib Tablets is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.

Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact.

Take Lorlatinib Tablets at the same time each day. If a dose is missed, then take the missed dose unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose.

Do not take an additional dose if vomiting occurs after Lorlatinib Tablets but continue with the next scheduled dose.


Lorlatinib may cause serious side effects including: hives, difficulty breathing, swelling of your face, lips, tongue, or throat, abnormal liver function tests, chest pain, new or a worsening irregular heartbeats pattern, nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, and yellowing of the skin or eyes


Lorlatinib should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15°to 30° C (59° to 86° F) [ Controlled Room Temperature]. Keep away from children.


Genetic testing should be indicated in order to detect whether a person is at higher risk of developing hypersensitivity.

Lorlatinib may not be added as a single agent when antiretroviral regimens are changed because of loss of the virologic response.

Patients with liver disease should be watchful and cautious in order to Lorlatinib because it can aggravate the condition.

In patients with Lorlatinib, conditions like immune reconstitution inflammatory syndrome, a change in body fat as well as an increased risk of heart attack may occur.

Lorlatinib is not recommended for use in infants who are under 3 months of age.

Sometimes serious hypersensitivity reactions have been associated with Lorlatinib.

FAQs – Medicine Questions

Lorlatinib Tablets 25 mg
What is lorlatinib used for?
Lorlatinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer in patients who have a certain type of abnormal anaplastic lymphoma kinase (ALK) gene. Your doctor will perform a test to check for the ALK gene before you use this medicine
How do you take lorlatinib?
Lorlatinib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Take lorlatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.
How fast does lorlatinib work?
Responses were rapid. The median time to first tumour response was just 1–4 months. Lorlatinib even maintains its clinical activity regardless of number of previous administrated TKIs. Here, we describe two cases with metastatic ALK-rearranged NSCLC who had pulmonary disease control with first-generation ALK inhibitor
Where can I buy lorlatinib Tablets?

You can buy lorlatinib Tablets from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.

What is the procedure to buy lorlatinib Tablets?

Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020   We will reply ASAP with the details of the lorlatinib Tablets price as well as procurement procedure.

Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

Who developed Lorlatinib?
Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC).


  1. Pfizer Ltd, Electronic medicines compendium (emc), [Revised on March 2021] [ Accessed on 17th August 2021], https://www.medicines.org.uk/emc/files/pil.10632.pdf
  2. Pfizer, US Food and Drug Administration, [Revised on March 2021] [ Accessed on 17th August 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
  3. Alice T Shaw et al; First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer; The New England Journal of Medicine; Published on 19/11/2020; Accessed on 17/08/2021; https://pubmed.ncbi.nlm.nih.gov/33207094